ENTA Enanta Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ENTA

Price (delayed)

$9.9

Market cap

$208.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.38

Enterprise value

$145.64M

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections ...

Highlights
The debt has grown by 4.9% YoY but it has contracted by 4.3% from the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 34% YoY
The equity has decreased by 33% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.enanta.com
Peers: ENZN VRTX JNJ ABBV

Key stats

What are the main financial stats of ENTA
Market
Shares outstanding
21.06M
Market cap
$208.48M
Enterprise value
$145.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.84
Earnings
Revenue
$79.2M
EBIT
-$125.85M
EBITDA
-$123.48M
Free cash flow
-$112.21M
Per share
EPS
-$6.38
Free cash flow per share
-$5.35
Book value per share
$10.29
Revenue per share
$3.78
TBVPS
$22.05
Balance sheet
Total assets
$462.28M
Total liabilities
$245.54M
Debt
$26.51M
Equity
$216.74M
Working capital
$360M
Liquidity
Debt to equity
0.12
Current ratio
6.73
Quick ratio
6.09
Net debt/EBITDA
0.51
Margins
EBITDA margin
-155.9%
Gross margin
100%
Net margin
-169%
Operating margin
-173.2%
Efficiency
Return on assets
-32.8%
Return on equity
-52.2%
Return on invested capital
-40.6%
Return on capital employed
-31.5%
Return on sales
-158.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENTA stock price

How has the Enanta Pharmaceuticals stock price performed over time
Intraday
1.96%
1 week
10.12%
1 month
18.56%
1 year
-76.41%
YTD
-78.72%
QTD
-11.37%

Financial performance

How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$79.2M
Gross profit
$79.2M
Operating income
-$137.21M
Net income
-$133.82M
Gross margin
100%
Net margin
-169%
The operating margin has contracted by 21% YoY and by 4.8% from the previous quarter
The net margin has contracted by 20% YoY and by 3.1% from the previous quarter
The company's operating income fell by 11% YoY and by 3% QoQ
ENTA's net income is down by 10% year-on-year

Growth

What is Enanta Pharmaceuticals's growth rate over time

Valuation

What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.96
P/S
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.84
The EPS has declined by 8% year-on-year
ENTA's P/B is 66% below its 5-year quarterly average of 2.8 and 59% below its last 4 quarters average of 2.3
The equity has decreased by 33% YoY and by 9% from the previous quarter
The price to sales (P/S) is 71% lower than the 5-year quarterly average of 9.0 and 67% lower than the last 4 quarters average of 7.7
Enanta Pharmaceuticals's revenue has decreased by 8% YoY

Efficiency

How efficient is Enanta Pharmaceuticals business performance
Enanta Pharmaceuticals's return on equity has shrunk by 50% YoY and by 12% QoQ
ENTA's return on invested capital is down by 12% year-on-year
The return on sales has declined by 12% year-on-year
Enanta Pharmaceuticals's ROA has decreased by 8% YoY but it has increased by 4.1% from the previous quarter

Dividends

What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTA.

Financial health

How did Enanta Pharmaceuticals financials performed over time
The company's total assets is 88% higher than its total liabilities
Enanta Pharmaceuticals's current ratio has decreased by 36% YoY but it has increased by 2.3% from the previous quarter
Enanta Pharmaceuticals's quick ratio has decreased by 34% YoY
The debt is 88% less than the equity
The company's debt to equity has surged by 50% YoY
The equity has decreased by 33% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.